-
Bispecific Antibodies_Rajat Bannerji, MD, PhD; #IUCLS22
20:34
-
Sequencing of Therapies in R/R MCL_Kami Maddocks, MD; #IUCLS22
18:16
-
How to Sequence Non-CAR T-cell Therapy for Relapsed/Refractory DLBCL_Daniel Landsburg, MD; #IUCLS22
20:37
-
Venous Thromboembolism in Lymphoma: Risk Stratification, Prophylaxis, and Treatment _Kenneth Cohen, MD; #IUCLS22
42:01
-
Biology of Follicular Lymphoma_Robert Kridel, MD, MPH, PhD; #IUCLS22
20:24
-
We Should Stop Doing Autotransplants for Patients with Mantle Cell Lymphoma in First Remission_Patrick Stiff, MD; #IUCLS22
15:00
-
Autologous HTC Remains the Preferred Standard of Care for First-line Therapy of Mantle Cell Lymphoma_Timothy Fenske, MD; #IUCLS22-01
18:15
-
Impact of the Immune Landscape on Hodgkin Lymphoma Prognosis and Treatment_Christian Steidl, MD; #IUCLS22
19:49
-
Post-Acute Outcomes after Hodgkin Lymphoma: An Epidemiologic Perspective_Lindsay Morton, PhD; #IUCLS22
21:00
-
Prevention of CNS Progression in Diffuse Large B-cell Lymphoma_Craig Portell, MD; #IUCLS22
19:43
-
Hodgkin's Lymphoma: Relapse After Auto SCT, Brentuximab Vedotin, and Checkpoint Inhibitors – The Next Frontier_Anna Sureda, MD, PhD; #IUCLS22
20:00
- Next Page